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TDP-43 liquid-liquid phase separation (LLPS) deficiency attenuates 
amyloid beta deposition in the 5XFAD transgenic mouse model of 
Alzheimer’s Disease
Nathan Ramachandran, Xiaojia Ren, Ph.D, Ju Gao, M.D., Luwen Wang, Ph.D, Ariele Peters, Justin 
Dunn, Xinglong Wang, Ph.D.








TDP-43 with inhibited liquid-liquid phase separation properties attenuate the amyloid plaques in the brain of 5xFAD mice.
(A) Representative images of dense core plaques (Thio-S) in the subiculum, cortex, and hippocampus of 5xFAD mice and
5xFAD/TDPΔCR mice.
(B) Quantification of plaque load of Thio-S positive plaques in whole brain, presented by the ratio of plaque area to whole brain area, n=2.
(C) Representative images of immunohistochemistry staining of 6E10 at hippocampus of Non-Tg, TDPΔCR, 5xFAD, and 5xFAD/TDPΔCR
mice. Data is analyzed with Student’s t-test and shown in means± s.e.m., **p<0.01.
Phase separation-deficient TDP-43 does not protect the brains of 5xFAD mice from the loss of neurons at subiculum area.
(A) Representative images of immunohistochemistry staining of NeuN at subiculum of Non-Tg, TDPΔCR, 5xFAD, 5xFAD/TDPΔCR mice.
(B) Quantification of immunohistochemistry staining of NeuN at subiculum area of Non-Tg, TDPΔCR, 5xFAD, and 5xFAD/TDPΔCR
mice, presented by the ratio of number of NeuN-positive cells to the area of subiculum, n=2-5. Data is analyzed with One-Way of




Microgliosis and astrogliosis in hippocampus of 5xFAD mice are partially prevented by LLPS-deficient TDP-43
(A) Representative images of immunohistochemistry staining of GFAP, and Iba1, respectively, at hippocampus of Non-Tg, TDPΔCR, 5xFAD, and
5xFAD/TDPΔCR mice.
(B) Quantification of immunohistochemistry staining of GFAP and Iba1 at hippocampus area of Non-Tg, TDPΔCR, 5xFAD, and 5xFAD/TDPΔCR mice,
presented by the ratio of number of GFAP-positive or Iba1-positive cells to the area of hippocampus, n=2-4. Data is analyzed with One-Way of Variance
(ANOVA) followed by Tukey’s multiple comparison test, shown in means± s.e.m., *p<0.05.
The correlation between TDP-43 LLPS and AD deposition is an 
intriguing, yet currently unexplored area of interest. The purpose 
of this study is to investigate whether and how TDP-43 and its 
phase separation are involved in amyloid deposition in APP 
transgenic mice for Alzheimer’s Disease.
TAR DNA-binding protein 43 (TDP-43) can be found within the 
cell nucleus in most tissues and is a fundamental component to 
protein production, as it works to slice and reconfigure mRNA 
molecules. Recently, TDP-43 inclusions have been identified as a 
prevalent proteinopathy in the brains of individuals diagnosed 
with Alzheimer’s Disease (AD). However, despite the growing 
body of evidence demonstrating the important role of TDP-43 in 
AD pathogenesis, whether and how TDP-43 proteinopathy and 
other AD pathological hallmarks interact remain largely 
unknown. Furthermore, TDP-43 has a high propensity to 
undergo liquid-liquid phase separation (LLPS), a biological 
process necessary for the condensation of proteins, nucleic acids, 
and other biomolecules.
Background
We crossed our recently generated mice expressing endogenous 
LLPS-deficient murine TDP-43 with the widely used 5XFAD 
transgenic mouse model. Different approaches were then performed 
to assess amyloid deposition and associated neuroinflammation. 
Methods Acknowledgements
When compared to 5XFAD mice, 5xFAD mice expressing LLPS-deficient TDP-43 showed 
significantly reduced amyloid deposition throughout the brain. Neuroinflammation, 
as evaluated by GFAP and Iba1 expression, was also alleviated by LLPS-deficient TDP-
43. For the first time, our study demonstrates the likely role  TDP-43 LLPS plays in 
amyloid deposition. And, targeting TDP-43 LLPS may serve as a novel therapeutic 
approach to Alzheimer’s Disease treatment. 
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